{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:17:48Z","timestamp":1783127868917,"version":"3.54.6"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.yebeh.2021.108515","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T12:26:21Z","timestamp":1641212781000},"page":"108515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6\u201316\u202fyears"],"prefix":"10.1016","volume":"127","author":[{"given":"Pierangelo","family":"Veggiotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiusz","family":"J\u00f3zwiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenella","family":"Kirkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"Ikedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.108515_b0005","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b, f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J Med Chem"},{"issue":"Suppl. 6","key":"10.1016\/j.yebeh.2021.108515_b0010","first-page":"257","article-title":"Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels (poster p851)","volume":"52","author":"Hebeisen","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108515_b0015","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0197-0186(01)00101-2","article-title":"The novel anticonvulsant BIA 2\u2013093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine","volume":"40","author":"Parada","year":"2002","journal-title":"Neurochem Int"},{"key":"10.1016\/j.yebeh.2021.108515_b0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide","volume":"89","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yebeh.2021.108515_b0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40268-017-0197-5","article-title":"Eslicarbazepine acetate: a new improvement on a classic drug family for the treatment of partial-onset seizures","volume":"17","author":"Galiana","year":"2017","journal-title":"Drugs R D"},{"key":"10.1016\/j.yebeh.2021.108515_b0030","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/0091270005279364","article-title":"Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2\u2013093) in healthy elderly and young subjects","volume":"45","author":"Almeida","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.108515_b0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-1211(01)00231-5","article-title":"Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine","volume":"44","author":"Hainzl","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108515_b0040","unstructured":"European Medicines Agency. Zebinix: EPAR - Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zebinix-epar-product-information_en.pdf; 2021 [accessed 6 July 2021]."},{"key":"10.1016\/j.yebeh.2021.108515_b0045","unstructured":"US Food and Drug Administration. APTIOM\u00ae: Prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022416s011lbl.pdf; 2019 [accessed 12 July 2021]."},{"key":"10.1016\/j.yebeh.2021.108515_b0050","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/01.WNL.0000115653.82763.07","article-title":"Cognitive side effects of antiepileptic drugs in children","volume":"62","author":"Loring","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108515_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2018.01.029","article-title":"Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures","volume":"81","author":"Jozwiak","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108515_b0060","series-title":"ECDEU Assessment Manual for Psychopharmacology - Revised (DHHS Publ No ADM 91-338)","author":"Guy","year":"1976"},{"key":"10.1016\/j.yebeh.2021.108515_b0065","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108515_b0070","doi-asserted-by":"crossref","unstructured":"Halasz P, Cramer JA, Hodoba D, Czlonkowska A, Guekht A, Maia J, Elger C, Almeida L, Soares-da-Silva P. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 2010;51: 1963-9. https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02660.x","DOI":"10.1111\/j.1528-1167.2010.02660.x"},{"key":"10.1016\/j.yebeh.2021.108515_b0075","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.eplepsyres.2012.07.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study","volume":"103","author":"Hufnagel","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108515_b0080","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108515_b0085","doi-asserted-by":"crossref","unstructured":"Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50: 454-63. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01946.x.","DOI":"10.1111\/j.1528-1167.2008.01946.x"},{"key":"10.1016\/j.yebeh.2021.108515_b0090","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.108515_b0095","doi-asserted-by":"crossref","first-page":"106962","DOI":"10.1016\/j.yebeh.2020.106962","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial","volume":"105","author":"Kirkham","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108515_b0100","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/epi.16069","article-title":"Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy","volume":"60","author":"Wechsler","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108515_b0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0883073819890997","article-title":"Safety and tolerability of adjunctive eslicarbazepine acetate in pediatric patients (aged 4\u201317 years) with focal seizures","volume":"35","author":"Mintz","year":"2020","journal-title":"J Child Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:44:47Z","timestamp":1761504287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021007769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":21,"alternative-id":["S1525505021007769"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108515","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6\u201316\u202fyears","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108515"}}